Butabarbital decreases consequences of sufentanil SL by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Closely. Coadministration of CYP3A4 inducers may possibly lessen sufentanil ranges and efficacy, quite possibly precipitating withdrawal syndrome in patients who may have designed physical dependence to sufentanil. Discontinuation of concomitantly used CY... https://carlg791dee5.wikiexcerpt.com/user